Cargando…

Why Target the Gut to Treat IgA Nephropathy?

Detalles Bibliográficos
Autores principales:	Barratt, Jonathan, Rovin, Brad H., Cattran, Daniel, Floege, Jürgen, Lafayette, Richard, Tesar, Vladimir, Trimarchi, Hernán, Zhang, Hong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7569689/ https://www.ncbi.nlm.nih.gov/pubmed/33102954 http://dx.doi.org/10.1016/j.ekir.2020.08.009

Ejemplares similares

International Physicians Delphi Survey: Managing Patients With IgA Nephropathy
por: Floege, Jürgen, et al.
Publicado: (2022)

Safety, Tolerability and Efficacy of Narsoplimab, a Novel MASP-2 Inhibitor for the Treatment of IgA Nephropathy
por: Lafayette, Richard A., et al.
Publicado: (2020)

IgA nephropathy: a perspective for 2021
por: Floege, Jürgen, et al.
Publicado: (2021)

Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study
por: Rizk, Dana V., et al.
Publicado: (2023)

Challenges in IgA Nephropathy Management: An Era of Complement Inhibition
por: Tesař, Vladimir, et al.
Publicado: (2023)

Implementing the Kidney Health Initiative Surrogate Efficacy Endpoint in Patients With IgA Nephropathy (the PROTECT Trial)
por: Barratt, Jonathan, et al.
Publicado: (2019)

IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study
por: Barratt, Jonathan, et al.
Publicado: (2023)

Current treatment of IgA nephropathy
por: Floege, Jürgen, et al.
Publicado: (2021)

Emerging Modes of Treatment of IgA Nephropathy
por: Maixnerova, Dita, et al.
Publicado: (2020)

Crescents and IgA Nephropathy: A Delicate Marriage
por: Trimarchi, Hernán, et al.
Publicado: (2022)

Expanding options of supportive care in IgA nephropathy
por: Maixnerova, Dita, et al.
Publicado: (2023)

New insights into the pathogenesis of IgA nephropathy
por: Yeo, See Cheng, et al.
Publicado: (2017)

The coincidence of IgA nephropathy and Fabry disease
por: Maixnerová, Dita, et al.
Publicado: (2013)

Galactose-deficient IgA1 and the corresponding IgG autoantibodies predict IgA nephropathy progression
por: Maixnerova, Dita, et al.
Publicado: (2019)

New strategies and perspectives on managing IgA nephropathy
por: Selvaskandan, Haresh, et al.
Publicado: (2019)

Gross hematuria following vaccination for severe acute respiratory syndrome coronavirus 2 in 2 patients with IgA nephropathy
por: Negrea, Lavinia, et al.
Publicado: (2021)

IgA Nephropathy Genetic Risk Score to Estimate the Prevalence of IgA Nephropathy in UK Biobank
por: Sukcharoen, Kittiya, et al.
Publicado: (2020)

Noninvasive Urinary Monitoring of Progression in IgA Nephropathy
por: Yang, Joshua Y. C., et al.
Publicado: (2019)

Correction: Galactose-deficient IgA1 and the corresponding IgG autoantibodies predict IgA nephropathy progression
por: Maixnerova, Dita, et al.
Publicado: (2019)

pSTAT1 Is Activated during the Progression of IgA Nephropathy
por: Tao, Jianling, et al.
Publicado: (2022)

Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments
por: Coppo, Rosanna, et al.
Publicado: (2014)

Effect of Immunosuppressive Drugs on the Changes of Serum Galactose-Deficient IgA1 in Patients with IgA Nephropathy
por: Kim, Min Jeong, et al.
Publicado: (2016)

New Insights into the Pathogenesis and Treatment Strategies in IgA Nephropathy
por: Scionti, Katrin, et al.
Publicado: (2021)

IgA Nephropathy: A Tale of 3 Continents
por: Tang, Sydney Chi-Wai
Publicado: (2021)

An Update on the Current State of Management and Clinical Trials for IgA Nephropathy
por: Cheung, Chee Kay, et al.
Publicado: (2021)

Monitoring Immune Responses in IgA Nephropathy: Biomarkers to Guide Management
por: Selvaskandan, Haresh, et al.
Publicado: (2020)

Targeting the Endothelin A Receptor in IgA Nephropathy
por: Kohan, Donald E., et al.
Publicado: (2023)

The Non-Coding RNA Landscape in IgA Nephropathy—Where Are We in 2021?
por: Pawluczyk, Izabella Z. A., et al.
Publicado: (2021)

Single versus dual blockade of the renin-angiotensin system in patients with IgA nephropathy
por: Lennartz, David Paul, et al.
Publicado: (2020)

Intestinal permeability in patients with IgA nephropathy and other glomerular diseases: an observational study
por: Seikrit, Claudia, et al.
Publicado: (2022)

The Role of IgA in the Pathogenesis of IgA Nephropathy
por: Perše, Martina, et al.
Publicado: (2019)

Significance of segmental glomerulosclerosis in IgA nephropathy: What is the evidence?
por: Mubarak, Muhammed, et al.
Publicado: (2013)

Urokinase-type plasminogen activator receptor in IgA nephropathy
por: Ahn, Shin-Young, et al.
Publicado: (2014)

How to optimize the design and implementation of risk prediction tools: focus group with patients with IgA nephropathy
por: Gagliardi, Anna R., et al.
Publicado: (2020)

Outcome of 313 Czech Patients With IgA Nephropathy After Renal Transplantation
por: Maixnerova, Dita, et al.
Publicado: (2021)

External Validation of International Risk-Prediction Models of IgA Nephropathy in an Asian-Caucasian Cohort
por: Zhang, Yuemiao, et al.
Publicado: (2020)

IgA Nephropathy in a Patient Treated with Adalimumab
por: Mertelj, Tonja, et al.
Publicado: (2021)

Is There a Role for Gut Microbiome Dysbiosis in IgA Nephropathy?
por: Monteiro, Renato C., et al.
Publicado: (2022)

IgA Vasculitis and IgA Nephropathy: Same Disease?
por: Pillebout, Evangeline
Publicado: (2021)

New Treatment Strategies for IgA Nephropathy: Targeting Plasma Cells as the Main Source of Pathogenic Antibodies
por: Maixnerova, Dita, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_krkm0cv181hsu1m5kutq0oct0g